Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02548078
Recruitment Status : Completed
First Posted : September 14, 2015
Results First Posted : May 3, 2018
Last Update Posted : May 3, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:

The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.

Considering the risk of exposure to Ebola and the potential (based on animal data) for the investigational GSK3390107A (ChAd3-EBO-Z) vaccine to afford at least partial protection, all children in the study will receive the investigational GSK3390107A (ChAd3 EBO-Z) vaccine. The children in the Group GSK3390107A+Nimenrix will receive the investigational GSK3390107A (ChAd3-EBO-Z) vaccine at Day 0 of the study, whereas the children in the Group Nimenrix+GSK3390107A will receive Nimenrix at Day 0 (as a control). At Month 6, the children in the Group Nimenrix+GSK3390107A will receive the investigational GSK3390107A (ChAd3-EBO-Z) vaccine (provided that no safety concerns are raised), whereas the children in the Group GSK3390107A+Nimenrix will receive Nimenrix.


Condition or disease Intervention/treatment Phase
Virus Diseases Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A) Biological: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa
Actual Study Start Date : November 9, 2015
Actual Primary Completion Date : May 15, 2017
Actual Study Completion Date : May 15, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola

Arm Intervention/treatment
Experimental: GSK3390107A+Nimenrix Group
Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
A single dose administered intramuscular

Biological: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
A single dose administered intramuscular

Experimental: Nimenrix+GSK3390107A Group
Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
A single dose administered intramuscular

Biological: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
A single dose administered intramuscular




Primary Outcome Measures :
  1. Number of Subjects With Solicited Local Symptoms, Overall [ Time Frame: During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited local symptoms included: pain and swelling at the injections site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = crying at limb movement/spontaneous pain.Grade 3 swelling = swelling extending on a surface higher than (>) 30 millimeters (mm). Solicited local symptoms, for this endpoint, were assessed in all subjects, in both groups.

  2. Number of Subjects With Solicited Local Symptoms, by Age Stratum [ Time Frame: During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited local symptoms included: pain and swelling at the injections site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = crying at limb movement/spontaneous pain.Grade 3 swelling = swelling extending on a surface higher than (>) 30 millimeters (mm), for children between 1-5 years old; > 50 mm for children between 6-12 years old and >100 mm for children between 13-17 years old.

  3. Number of Subjects With Solicited General Symptoms, Overall [ Time Frame: During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Solicited general symptoms assessed included: fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain], headache, drowsiness, irritability/fussiness and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 fatigue/headache/drowsiness/gastrointestinal symptoms = fatigue/headache/drowsiness/gastrointestinal symptoms that prevented normal activity. Grade 3 fever = temperature > 39.5°C. Grade 3 irritability/fussiness = crying that couldn't be comforted. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as related to the vaccination. Solicited general symptoms, for this endpoint, were assessed in all subjects, in both groups.

  4. Number of Subjects With Solicited General Symptoms, by Age Stratum [ Time Frame: During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Solicited general symptoms assessed included: fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain], headache, drowsiness, irritability/fussiness and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 fatigue/headache/drowsiness/gastrointestinal symptoms = fatigue/headache/drowsiness/gastrointestinal symptoms that prevented normal activity. Grade 3 fever = temperature > 39.5°C. Grade 3 irritability/fussiness = crying that couldn't be comforted. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as related to the vaccination. Solicited general symptoms, for this endpoint, were assessed in subjects aged 1-5 years, 6-12 years and 13-17 years. Symptoms with no values were not assessed for those specific age groups.

  5. Number of Subjects With Unsolicited Adverse Events (AEs), Overall [ Time Frame: During the 30-day follow-up period after each vaccination (i.e. the day of vaccination and 29 subsequent days) ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited adverse events, for this endpoint, were assessed in all subjects, in both groups.

  6. Number of Subjects With Unsolicited Adverse Events (AEs), by Age Stratum [ Time Frame: During the 30-day follow-up period after each vaccination (i.e. the day of vaccination and 29 subsequent days) ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs, for this endpoint, were assessed in subjects between 1-5 years of age, 6-12 years of age and 13-17 years of age.

  7. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Screening. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  8. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Screening ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  9. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Day 3. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  10. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 3 ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  11. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Day 6. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  12. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 6 ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  13. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Day 30. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  14. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 30 ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  15. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Month 6. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  16. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  17. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Month 6 + 6 Days. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  18. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 + 6 Days ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  19. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Month 6 + 30 Days. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  20. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 + 30 Days ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  21. Percentage of Subjects With Haematological Laboratory Abnormalities, Overall [ Time Frame: At Month 12. ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  22. Percentage of Subjects With Haematological Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 12 ]
    Haematological parameters assessed included: complete blood count (red blood cells [RBC], neutrophils, lymphocytes, white blood cells [WBC], haemoglobin, as well as differential count and platelet count for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  23. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Screening. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  24. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Screening ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  25. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Day 3. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  26. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 3 ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  27. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Day 6. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  28. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 6 ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  29. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Day 30. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  30. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Day 30 ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  31. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Month 6. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  32. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  33. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Month 6 + 6 Days. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  34. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 + 6 Days ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  35. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Month 6 + 30 Days. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  36. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 6 + 30 Days ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  37. Percentage of Subjects With Biochemical Laboratory Abnormalities, Overall [ Time Frame: At Month 12. ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for all subjects, in both groups. Reference range indicators used were: high, low, normal.

  38. Percentage of Subjects With Biochemical Laboratory Abnormalities, by Age Stratum [ Time Frame: At Month 12 ]
    Biochemical parameters assessed included: alanine aminotransferase [ALT], creatinine [CRE] for subjects aged 1-5 years, 6-12 years and 13-17 years. Reference range indicators used were: high, low, normal.

  39. Number of Subjects With Adverse Events of Specific Interest (AESI), Overall [ Time Frame: During the 7 day follow-up period after vaccination at Day 0 (i.e., Day 0 up to Day 6) ]
    AESI included clinical symptoms of thrombocytopenia for all subjects, in both groups.

  40. Number of Subjects With Adverse Events of Specific Interest (AESI), by Age Stratum [ Time Frame: During the 7 day follow-up period after vaccination at Day 0 (i.e. Day 0 up to Day 6) ]
    AESI included clinical symptoms of thrombocytopenia for subjects aged 1-5 years, 6-12 years and 13-17 years.

  41. Number of Subjects With Serious Adverse Events, Overall [ Time Frame: During the entire study period: From Screening to Month 12 ]
    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. SAEs, for this endpoint, were assessed in all subjects, in both groups.

  42. Number of Subjects With Serious Adverse Events, by Age Stratum [ Time Frame: During the entire study period: From Screening to Month 12 ]
    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. SAEs, for this endpoint, were assessed in subjects aged 1-5 years, 6-12 years and 13-17 years.


Secondary Outcome Measures :
  1. Anti-glycoprotein (GP) Ebola Virus Zaire (EBOV) Antibody Titers, Overall [ Time Frame: At Day 0, Day 30, Month 6, Month 6 + 30 Days and Month 12. ]
    Anti-GP EBOV antibodies were expressed as Geometric Mean Titers (GMTs), as measured by the Enzyme-Linked Immunosorbent Assay (ELISA) and assessed in all subjects, in both groups.

  2. Anti-GP EBOV Antibody Titers, by Age Stratum [ Time Frame: At Day 0, Day 30, Month 6, Month 6 + 30 Days and Month 12 ]
    Anti-GP EBOV antibodies were expressed as Geometric Mean Titers (GMTs), as measured by the Enzyme-Linked Immunosorbent Assay (ELISA) and assessed in subjects aged 1-5 years, 6-12 years and 13-17 years.

  3. Percentage of Seronegative/Seropositive Subjects for Anti-GP EBOV Antibodies, Overall [ Time Frame: At Day 0, Day 30, Month 6 and Month 6 + 30 Days. ]
    A seronegative subject is a subject whose titer is below the cut-off value. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value. The analysis, for this endpoint, was performed on all subjects, in both groups.

  4. Percentage of Seronegative/Seropositive Subjects for Anti-GP EBOV Antibodies, by Age Stratum [ Time Frame: At Day 0, Day 30, Month 6 and Month 6 + 30 Days ]
    A seronegative subject is a subject whose titer is below the cut-off value. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value. The analysis, for this endpoint, was performed on subjects aged 1-5 years, 6-12 years and 13-17 years.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject's parent(s)/ legally acceptable representative(s) (LAR[s]) who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g. availability for Diary Card completion, return for follow-up visits, availability for clinical follow-up throughout the study period).
  • Written/ thumb printed informed consent obtained from the subject' parent(s)/ LAR[s] prior to performing any study specific procedure. In addition, written/ thumb printed in-formed assent should be obtained if appropriate (from all subjects aged 13 to 17 years and from younger subjects as per local requirements).
  • A male or female child aged 1 to 17 years inclusive at the time of Screening.
  • Subjects with a negative RDT test for Malaria within 30 days prior to randomisation into the study.

OR Subjects with a positive RDT test for Malaria who completed antimalarial treatment at least 5 days prior to randomisation into the study.

  • Healthy subjects as per Investigator judgement, as estab-lished by medical history, clinical examination and haema-tology/ biochemistry laboratory parameters screening be-fore entering into the study.
  • Female subjects of non-childbearing potential may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche or ovariectomy.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to the Day 0 visit, and
    • has a negative pregnancy test at the Day 0 visit, and
    • has agreed to continue adequate contraception until 30 days after the Month 6 visit

Exclusion Criteria:

  • Child in care.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the Day 0 visit, or planned use during the study period.
  • Previous vaccination with an investigational EBOV or Marburg vaccine, or previous vaccination with a chim-panzee adenoviral vectored investigational vaccine.
  • Known prior EBOV or SUDV disease.
  • Travel to country affected by the EBOV epidemic or direct contact with person with EVD within 21 days prior to the Day 0 visit.
  • History of any reaction or hypersensitivity (such as ana-phylaxis, urticaria (hives), respiratory difficulty, angioe-dema, or abdominal pain) likely to be exacerbated by any component of the study vaccine.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each vaccination visit.
  • Acute or chronic illness determined by medical history, clinical examination and laboratory screening tests in-cluding, but not limited to:
  • Clinically significant immunosuppressive or immunodeficient condition (e.g. clinical acquired immune deficiency syndrome [AIDS]).
  • Major congenital defects.
  • Malnutrition (defined as weight for age Z-score less than -3, or other clinical signs of malnutrition).
  • Any clinically significant haematological or biochemical laboratory abnormality.
  • Pregnant female.
  • Any condition that in the Investigator's opinion may po-tentially compromise subject safety or interfere with sub-ject assessment or compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02548078


Locations
Layout table for location information
Mali
GSK Investigational Site
Bamako, Mali
Senegal
GSK Investigational Site
Dakar, Senegal
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:
Study Protocol  [PDF] August 12, 2015
Statistical Analysis Plan  [PDF] June 14, 2017


Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02548078     History of Changes
Other Study ID Numbers: 202090
2014-004714-28 ( EudraCT Number )
First Posted: September 14, 2015    Key Record Dates
Results First Posted: May 3, 2018
Last Update Posted: May 3, 2018
Last Verified: March 2018
Keywords provided by GlaxoSmithKline:
Protection against Ebola Zaire virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs